Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease (2018)
- Autor:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1080/14656566.2018.1476491
- Subjects: SÍNDROME CORONARIANA AGUDA; FÁRMACOS (SISTEMA CARDIOVASCULAR); INFARTO DO MIOCÁRDIO
- Language: Inglês
- Imprenta:
- Source:
- Título: Expert opinion on pharmacotherapy
- ISSN: 1465-6566
- Volume/Número/Paginação/Ano: v. 19, n. 9, p. 1013-1019, 2018
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
NICOLAU, Jose C. Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease. Expert opinion on pharmacotherapy, v. 19, n. 9, p. 1013-1019, 2018Tradução . . Disponível em: https://doi.org/10.1080/14656566.2018.1476491. Acesso em: 23 jan. 2026. -
APA
Nicolau, J. C. (2018). Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease. Expert opinion on pharmacotherapy, 19( 9), 1013-1019. doi:10.1080/14656566.2018.1476491 -
NLM
Nicolau JC. Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease [Internet]. Expert opinion on pharmacotherapy. 2018 ; 19( 9): 1013-1019.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1080/14656566.2018.1476491 -
Vancouver
Nicolau JC. Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease [Internet]. Expert opinion on pharmacotherapy. 2018 ; 19( 9): 1013-1019.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1080/14656566.2018.1476491 - P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes
- Impact of the Extent of Coronary and Myocardial Disease on the Treatment Effect of Surgical Revascularization in Patients With Ischemic Left Ventricular Dysfunction
- Doença arterial coronariana aguda
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
- Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
Informações sobre o DOI: 10.1080/14656566.2018.1476491 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
